Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by priceless2on Dec 09, 2019 11:51am

147 Views

Post# 30436016

RE:RE:Constellation Pharma up 152% on positive CPI-0610 data

Bear,

If Constellation has current market cap of 1.5 USd billion and based on their phase 2 trial results i would think that if Zenith Epigenetics was on the Nasdaq would have a simlar market valuation? , Yet the last Zenith PP were $2US so only a $500 Million Cad valuation based on sahres outstanding, Does the market discount Canadian based biotechs or is $1.5 Billion USd a good starting point for a buyout of Zenith Epigenetic??

Here is hoping for a buyout or partnership of Zenith

Bullboard Posts

Catch up with companies that got a Stanley Cup Playoffs boost